| 词条 | Galcanezumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = zu | target = CALCA, CALCB | tradename = Emgality | synonyms = LY2951742 | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1578199-75-3 | ATC_prefix = N02 | ATC_suffix = CX08 | PubChem = | ChemSpiderID = none | DrugBank = DB14042 | C = 6392 | H = 9854 | N = 1686 | O = 2018 | S = 46 | molecular_weight = 144.1 kDa | UNII = 55KHL3P693 | KEGG = D10936 }} Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[1][2] It is directed against calcitonin-related polypeptides alpha and beta. This drug was developed by Eli Lilly & Co. {{as of|2017|7}}.[3] The drug was approved by the US FDA in September 2018, becoming the third marketed CGRP inhibitor for the United States.[4] See also
References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Galcanezumab, American Medical Association. {{monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{nervous-system-drug-stub}}{{monoclonal-antibody-stub}}2. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}} 3. ^{{cite journal | author = H. Spreitzer | date = 3 July 2017 | title = Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab | journal = Österreichische Apothekerzeitung | issue = 14/2017 | language = German }} 4. ^{{Cite news|url=https://www.cnbc.com/2018/09/28/us-fda-approves-lilly-migraine-drug-at-a-price-that-is-the-same-as-its-rivals.html|title=US FDA approves Lilly migraine drug at a price that is the same as its rivals|last=|first=|date=28 September 2018|work=CNBC|access-date=29 September 2018|agency=Reuters}} 3 : Monoclonal antibodies|Calcitonin gene-related peptide receptor antagonists|Eli Lilly and Company |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。